Spinraza fda approval december 2016?

What was the FDA approval date for Spinraza (nusinersen)?

Spinraza (nusinersen) was approved by the U.S. Food and Drug Administration (FDA) in December 2016 for the treatment of spinal muscular atrophy (SMA). [1]

What did the FDA approve Spinraza to treat in 2016?

The 2016 approval covered patients with spinal muscular atrophy, a genetic neuromuscular disease. [1]

Why was Spinraza significant at its December 2016 approval?

Spinraza was the first FDA-approved treatment for SMA, marking the start of disease-modifying therapy for the condition in the United States. [1]

Sources

1. https://www.drugpatentwatch.com/patent/Spiranza